• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Jupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    12/19/24 5:00:18 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email
    false 0001679628 0001679628 2024-12-15 2024-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 15, 2024

     

    JUPITER NEUROSCIENCES, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-41265   47-4828381
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File
    Number)
      (IRS Employer
    Identification No.)

     

    1001 North US HWY 1, Suite 504

    Jupiter, FL

      33477
    (Address of Principal Executive Offices)   (Zip Code)

     

    (561) 406-6154

    (Registrant’s Telephone Number, Including Area Code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   JUNS   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On December 15, 2024, Jupiter Neurosciences, Inc. (the “Company”) entered into a Strategic Services Agreement (the “Dominant Treasure Agreement”) with Dominant Treasure Health Company Limited (“Dominant Treasure”). Pursuant to the terms of the Dominant Treasure Agreement, Dominant Treasure agreed to provide certain services to the Company to assist the Company in accelerating the Company’s desire to get its products developed and distributed in the Southeast Asian market. In exchange for Dominant Treasure’s services pursuant to the Dominant Treasure Agreement, the Company agreed to pay Dominant Treasure a one-time payment of $2,300,000. In addition, if Dominant Treasure is involved in generating negotiations and conclusion of a distribution agreement for the Company in the countries of China (including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee of 5% of any upfront and/or milestone payments to be received by the Company. If such agreement will include a royalty payment to the Company, Dominant Treasure will receive 5% of such royalty payment. The Dominant Treasure Agreement has a term of 36 months and may be terminated at any time upon mutual agreement of the parties.

     

    The foregoing summary of the Dominant Treasure Agreement is qualified in its entirety by reference to the full text of the Dominant Treasure Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 9.01 Financial Statement and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1   Strategic Services Agreement, dated December 15, 2024, by and between Jupiter Neurosciences, Inc. and Dominant Treasure Health Company Limited.
    104.1   Cover Page Interactive Data File - the cover page XBRL tags are embedded with the Inline XBRL document.

     

     
     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      JUPITER NEUROSCIENCES, INC.
       
    Dated:  December 19, 2024 By: /s/ Christer Rosén
        Christer Rosén
        Chief Executive Officer

     

     

     

     

    Get the next $JUNS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Pres + Chief Business Officer Silva Alison D.

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/7/25 9:28:07 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Secretary Elmasri Saleem converted options into 66,293 shares (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/7/25 9:28:09 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

      Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL™, over conventional resveratrol formulations. Unlocking Resveratrol's Therapeutic Promise Resveratrol is one of the world's most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has

      7/23/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

      Nasdaq compliance follows positive upward trend in Company's Stock Price  Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company's Current Report on Form 8-K filed on July 10, 2025. On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as

      7/10/25 4:05:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

      PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, proje

      6/30/25 3:15:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    SEC Filings

    See more
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      7/10/25 5:08:19 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      7/9/25 4:40:39 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Jupiter Neurosciences Inc.

      10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      5/15/25 4:31:24 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care